By Michael Levenson 23andMe, the genetic testing company that was once valued at $6 billion but filed for bankruptcy in March, will be bought by Regeneron Pharmaceuticals, a biotechnology company ...

Would the cost-cutting measures for U.S. prescription drugs proposed by the Trump administration on Monday hurt the biotech sector more than pharma? We asked Seeking Alpha analysts Stephen Ayers ...

To get caught up, we’re rounding up all the hires, appointments, and promotions we heard about in the pharma and biotech world in the months of May and June. Stay tuned for more round-ups ...

Pharmaceutical manufacturing encompasses all processes involved in the manufacturing and production of biological and medical products, botanical drugs, and herbs, as well as other pharmaceutical ...

Twenty years ago, the American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable (ACS GCIPR) launched with the goal of discussing common issues and learning from each member ...

We’re back on track this month with Changing Faces as we look back at the month in pharma and biotech hires and – especially this month – departures. Yes, a number of high-profile departures ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

Pharmaceutical maker Regeneron announced Monday it will buy genetic testing company 23andMe for $256 million following a bankruptcy auction. Regeneron said it will acquire 23andMe’s genomics ...

The pharmaceutical industry is expected to resist, citing potential impacts on research and profits, with legal challenges anticipated. The order's implementation and interaction with the ...

More importantly to consumers who have privacy concerns during the proceedings, the pharmaceutical company promised to adhere to 23andMe's existing privacy policy, saying it will "prioritize the ...

He said he expects the order will reduce the cost of pharmaceuticals by 30% to 80%. "Our Country will finally be treated fairly, and our citizens [sic] Healthcare Costs will be reduced by numbers ...